Everolimus Reduces Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures Abstract #266

Introduction: It has been demonstrated that everolimus, an mTOR inhibitor, has a potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures.
Aim(s): To evaluate the possible antiproliferative effects of RAD001 in a group of 20 human MTC in a primary culture.
Materials and methods: Twenty MTCs were dispersed in primary cultures, treated without or with 1 nM - 1 micro M RAD001, 10 nM SOM230, and/or 50 nM IGF-I. Cell viability and apoptosis were evaluated after 48 h and Calcitonin (CT) secretion was assessed after an 8 h incubation. Somatostatin receptor expression was investigated by quantitative PCR.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Chiara Zatelli

To read results and conclusion, please login ...

Further abstracts you may be interested in

#430 mTOR Inhibitors Hamper Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
Introduction: It has been demonstrated that mTOR inhibitors have potent anti-proliferative effects in a human Medullary Thyroid Carcinoma (MTC) cell line. We here explore the possible role of mTOR inhibitors, Everolimus and BEZ235 (which also inhibits the PI3K pathway) on the effects of Insulin-like Growth Factor-1 (IGF-1) in human MTC primary cultures.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mrs. Mariella Minoia
#2732 Prostate Metastasis of Medullary Thyroid Carcinoma in a Young Patient with MEN2B Syndrome
Introduction: Multiple Endocrine Neoplasia 2B is associated with particularly early onset medullary thyroid carcinoma (MTC). Metastatic MTC is the leading cause of early death in MEN2B. The usual sites of metastasis are neck, mediastinum, lung, liver, bone and brain.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Jane Noble
Authors: Noble J, Forde H, Crowley R, ...
#2813 Clinical Presentation and Prognosis of Patients with Medullary Thyroid Cancer
Introduction: Medullary thyroid carcinoma (MTC) is a rare type of tumor that originates from parafollicular C-cells and accounts for 3–4% of all malignant thyroid neoplasms. MTC presents as sporadic (75–80%) or inherited tumors (20–25%). Hereditary MTC is part of multiple endocrine neoplasia type 2 (MEN2).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Federica de Cicco
#3074 Medullary Thyroid Carcinoma and DIPNECH: An Unexpected Association
Introduction: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour of the C-cells of thyroid gland. Diffuse idiopathic pulmonary neuroendocrine cells hyperplasia (DIPNECH) is a rare condition, thought to be primarily a neuroendocrine proliferative process which can develop into carcinoid tumours.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Joana Lima Ferreira
#48 Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
Introduction: Medullary thyroid carcinoma (MTC) accounts for about 5-10% of all thyroid cancers, and while disease localized to the thyroid can be cured by surgery, there is no effective treatment for disseminated MTC. Constitutive activation of the RET proto-oncogene is implicated in familial and a proportion of sporadic cases, and up-regulates the AKT/PI3-kinase/mTOR signal transduction pathway. Recent studies have shown that the inhibitor of mTOR, everolimus (RAD001, Novartis, Basel), can inhibit the proliferation of the TT cell line and human MTC tumor cells in vitro. Clinically, everolimus has been shown to attenuate the progression of some gastrointestinal neuroendocrine tumors, but its clinical use in MTC has not yet been evaluated.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maralyn R Druce